Table 1.
Summary of payments to the authors of the Japanese clinical practice guidelines for dementia
| Variable | Total population (N = 61) |
|---|---|
| Affiliations | |
| University hospitals | 37 (60.7%) |
| Other types of hospitals | 13 (21.3%) |
| Research institutes | 3 (4.9%) |
| Clinics | 1 (1.6%) |
| Universities | 6 (9.8%) |
| Others | 1 (1.6%) |
| University professors∗ | |
| Yes | 18 (58.1%) |
| No | 25 (41.9%) |
| Guideline authors with payments (N, %)† | |
| Median (interquartile range) | $5.878 ($507–$20,875) |
| Mean (standard deviation) | $14,427 ($20,889) |
| Any | 49 (80.3%) |
| ≥5000 USD | 33 (54.1%) |
| ≥50,000 USD | 6 (9.8%) |
| Total sum of payments from pharmaceutical companies (top 5)† | |
| Daiichi-Sankyo Company, Limited | $205,032 |
| Eisai Co., Ltd. | $129,663 |
| Novartis International AG | $95,057 |
| Takeda Pharmaceutical Company Ltd. | $77,245 |
| Janssen Pharmaceuticals | $47,977 |
∗
Calculated for those working in universities (N = 43).
†
Currency exchange rate is 0.0091 USD per 1 Japan yen (as of May 14, 2019).